Physician profile
Alison Metherell Mann
NPI 1457433542
$579.98
in general payments reported to CMS, 2019-2025
15 companies · $267 in 2025
The $267 reported for 2025 was more than what 82% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.79 · 2020: $23.95 · 2021: $29.58 · 2022: $19.02 · 2023: $97.32 · 2024: $91.63 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $111.50 | 2019-2023 | |
| Glaxosmithkline, LLC. | $57.50 | 2023-2025 | Bexsero, Pediarix, Penmenvy |
| Ars Pharmaceuticals Operations, INC. | $51.94 | 2025 | Neffy |
| Alk-Abello, INC | $48.67 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $39.92 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $38.17 | 2025 | Vaxneuvance, Rotateq, Enflonsia |
| Neos Therapeutics, LP | $35.25 | 2025 | Cotempla Xr-Odt |
| Cranial Technologies, INC | $35.03 | 2023-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $27.38 | 2024 | Flumist Quadrivalent |
| Supernus Pharmaceuticals, INC. | $24.90 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.33 | 2024 | |
| Genentech USA, INC. | $23.95 | 2020 | |
| Krystal Biotech INC | $21.63 | 2025 | Vyjuvek |
| Kaleo, INC. | $20.79 | 2019 | |
| Seqirus USA INC | $19.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.